Search
Troleandomycin
go.drugbank.com/drugs/DB13179ApprovedA macrolide antibiotic that is similar to erythromycin.
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational_C. botulinum_ is known to produce toxins that can cause botulism in humans.
Decamethonium
go.drugbank.com/drugs/DB01245ApprovedDecamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. … It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalown infected B-cells, thereby helping to control this condition. … Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.
Guanadrel
go.drugbank.com/drugs/DB00226ApprovedGuanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Metamfetamine
go.drugbank.com/drugs/DB01577ApprovedIllicitInvestigationalWithdrawnIt is a scheduled drug in most countries due to its high potential for addiction and abuse.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSertraline
go.drugbank.com/drugs/DB01104ApprovedInvestigationalSertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: SERTRALINA SIGMA TAU GENERICS, SERTRALINA DOC GENERICIImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. … The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.
Products: IMATINIB DOC GENERICIGTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. … Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.